Based on data supporting the use of tumor necrosis factor (TNF) inhibitors in the steroid-sensitive setting and clinical practice, infliximab was used to manage the immune-mediated TRAE of diarrhea/colitis in this study even in the non-refractory low-grade setting28,29. The gene discussed is TNF; the disease is colitis.